My Wake Up Call: Bydureon and Possible Cancer Risk?

Email this to someoneTweet about this on Twitter0Share on Facebook0Share on Google+0Pin on Pinterest0

Last week, I attended  the Second Annual Diabetes Symposium at the Thomas Jefferson University. Surrounded by endocrinologists, nutritionists and diabetes educators, I sat through the lively presentations on new advances and innovations in diabetes. The news was not entirely encouraging — while the artificial pancreas seems on the horizon for type 1’s, the docs seemed somewhat stymied by the obesity problems of their patients, and most of the event centered around medications and what percentage of help old and new ones lent to rising A1C profiles.

But when Dr. Edwin Gale began to talk, my ears perked up; he addressed a topic near to my heart, diabetes and cancer. As a type 2 who has been injecting Byetta and then Bydureon for the larger part of four years, I had become alert to reports associating these drugs with pancreatitis and possible pancreatic cancer. And though Gale noted that diabetes did not seem to be in itself a cancer risk — unlike obesity — he talked about possibilities that these medications did carry certain risks of “subclinical injuries to the pancreas.” That this subclinical inflammation continued after even stopping the drug was further fuel for worry.

Sitting in the audience, already aware of the Hopkins studies, I began to get a little flutter in my stomach. When the presentation ended, I dashed up front to ask Dr. Gale a simple question: If he had a daughter, and she were on these drugs like Byetta and Bydureon, what might he tell her to do?

He didn’t hesitate. “Get off them at once.”

Needless to say, I was worried. So when I returned home, I called my endo. He called right back and we talked it over. He reminded me that these were new drugs, that there haven’t been long term studies and that there is a great deal of disagreement on these issues. But he didn’t really see any harm in my continuing on them. And yet. So we talked some more. And though I have been doing very well on Bydureon, I decided that I was going to take a break.

It wasn’t easy making the decision. I don’t think I’ve ever challenged my doctor’s knowledge before. But  for now I’m back on my old routine of Metformin and Amryl, few carbs if any, and lots of exercise. If, by January, my A1C takes a climb, I’ll have to reconsider. Stay tuned.

Email this to someoneTweet about this on Twitter0Share on Facebook0Share on Google+0Pin on Pinterest0

Comments (1)

  1. Rosalee at

    How are you doing without the Byetta?

Add a comment

Your email address will not be published. Required fields are marked *


*

You may use these HTML tags and attributes: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <strike> <strong>

***The opinions and views expressed in this blog belong to the individual contributor and not to ASweetLife or its editors. All information contained on this blog is intended for informational purposes only. The information is not intended to be a replacement or substitute for consultation with a qualified medical professional or for professional medical advice related to diabetes or another medical condition. Please contact your physician or medical professional with any questions and concerns about your medical condition.